Volcano Corporation
http://www.volcanocorp.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Volcano Corporation
Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback
The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.
Company Information
- Industry
-
Medical Devices
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Axsun Technologies, Inc. , Volcano Corp. Sync-RX, Crux Biomedical, AtheroMed
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice